Table 4 Comparison between morphological phenotype, genotype, grading and survival.
Morphological phenotype | Conventional ductal adenocarcinoma (without components) (A1) | Combined ductal adenocarcinoma (with additional components) (A2) | Variants (B) |
|---|---|---|---|
N | 91 | 72 | 14 |
KRAS | |||
Wildtype | 7 | 3 | 3 |
Mutated | 84 | 69 | 11 |
p-value A1 vs A21 | 0.35 | ||
p-value A vs B1 | 0.035 | ||
CDKN2A/p16 | |||
Intact | 29 | 11 | 3 |
Altered | 62 | 60 | 11 |
p-value A1 vs A21 | 0.016 | ||
p-value A vs B1 | 0.78 | ||
TP53 | |||
Intact | 22 | 11 | 5 |
Altered | 69 | 61 | 9 |
p-value A1 vs A21 | 0.16 | ||
p-value A vs B1 | 0.17 | ||
SMAD4 | |||
Intact | 57 | 45 | 10 |
Altered | 34 | 27 | 4 |
p-value A1 vs A21 | 0.98 | ||
p-value A vs B1 | 0.51 | ||
Number of mutations | |||
0 | 0 | 0 | 1 |
1 | 5 | 1 | 2 |
2 | 30 | 14 | 3 |
3 | 40 | 40 | 5 |
4 | 16 | 17 | 3 |
p-value A1 vs A21 | 0.09 | ||
p-value A vs B1 | 0.004 | ||
Pathologic stage | |||
Primary tumour | |||
T1 | 2 | 2 | 0 |
T2 | 3 | 8 | 0 |
T3 | 74 | 55 | 14 |
T4 | 12 | 7 | 0 |
p-value A1 vs A21 | 0.23 | ||
p-value A vs B1 | 0.55 | ||
Nodal status | |||
N0 | 24 | 22 | 7 |
N1 | 67 | 50 | 7 |
p-value A1 vs A21 | 0.60 | ||
p-value A vs B1 | 0.12 | ||
Grading | |||
G1 | 7 | 1 | 5 |
G2 | 4 | 27 | 6 |
G3 | 44 | 44 | 3 |
p-value A1 vs A21 | 0.08 | ||
p-value A vs B1 | <0.001 | ||
Survival | |||
(months) | 22.7 | 15.5 | 34.1 |
p-value A1 vs A22 | 0.07 | ||
p-value A vs B2 | 0.06 | ||
